The era of cheap, generic Ozempic is about to begin—and ...
Canada will soon be the first big market where copies of the hit weight-loss drug are legally sold. The country's generic drug-makers are drooling at the chance to cash in.
thelogic.coHere’s the latest on generic Ozempic in Canada:
-
Health Canada approved the first generic version of Ozempic (semaglutide) in late April 2026. The approval was for a generic semaglutide injection manufactured by Dr. Reddy’s Laboratories, following a safety, efficacy, and quality assessment. This marks a milestone in increasing competition and potentially reducing costs for patients using semaglutide in Canada. [Sources: CBC Canada Health news on Health Canada approval; Global News coverage of the approval date]
-
Ahead of formal approval, Canada’s regulator had begun accepting manufacturing applications from multiple companies as of late December 2025/early 2026, with several firms (e.g., Sz Canada Apot, Te Canada, Taro Pharmaceuticals, Aspen Pharmacare Canada, Sandoz Canada, Teva Canada) submitting to produce generic semaglutide. Industry observers expected it could take several months before generics reach pharmacies due to regulatory reviews, manufacturing timelines, and supply arrangements. [Sources: CBC and CTV/Global News reports on initial submissions and timing expectations]
-
Industry commentary in early 2026 emphasized that, while generics could be approved, patients should not expect immediate wide availability. Regulators and manufacturers anticipated a gradual rollout across provinces, with potential interim pricing advantages as competition increases. [Sources: CTV News quotes and Canadian health coverage]
-
Canadian physicians and policy experts noted that Canada is a unique market where patent/regulatory dynamics allowed generics for semaglutide sooner than many other places, which could lead to more affordable options for diabetes and weight-management therapy in the coming months. [Sources: CBC coverage on patent expiry and expert commentary]
-
For patients currently using Ozempic or Wegovy, expect continued access through brand-name products during the initial generic rollout, with health system and insurer programs likely to support transitions where appropriate. Novo Nordisk has indicated ongoing commitment to patient access and savings support during the transition period. [Sources: Global News interview with Novo Nordisk Canada leadership; CBC reporting on patient access considerations]
If you want, I can pull the most recent country-wide availability status, compare list prices across provinces, or summarize patient access programs from major insurers. I can also set up a quick country-by-country snapshot if you’re tracking price and access changes beyond Canada.
Citations:
- Health Canada approves 1st generic version of Ozempic[5]
- Canada generic Ozempic rollout and timing expectations[2][3][4]
- Canadian expert commentary on generics in Canada[3]
- Media coverage on regulatory and payer responses[7][8][9]